- Home
- ACRE vs ACHV Comparison
ACRE vs ACHV Comparison
Compare ACRE & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | ACHV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 239.0M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRE | ACHV |
|---|---|---|
| Price | $4.70 | $4.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.33 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 614.5K | 606.8K |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 12.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.65 | N/A |
| 52 Week Low | $3.35 | $1.84 |
| 52 Week High | $6.21 | $5.78 |
Technical Indicators
Market Signals| Indicator | ACRE | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 60.73 |
| Support Level | $5.02 | $4.30 |
| Resistance Level | $5.55 | $4.56 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 3.45 | 89.19 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.